Market Access News | pharmaphorum

News

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

News

Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.

News

Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated vasculitis from the US market.

News

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can now be used routinely by the NHS to monitor patients with heart failure.

News

The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department.

News

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.